Skip to main content
. Author manuscript; available in PMC: 2021 Mar 22.
Published in final edited form as: Chem Biol Drug Des. 2017 Nov 3;91(2):491–504. doi: 10.1111/cbdd.13110

FIGURE 3.

FIGURE 3

(a) In silico docking screen of the NCI diversity set 2. (b) Trial compounds from the NCI screen that were verified to be FGF23 antagonist in Xiao et al. with their IC50 values. Experimentally verified FGF23 inhibitors and their IC50 values. (c) In silico docking screen of the ZINC Drugs Now subset of the ZINC database. (d) Trial compounds from the ZINC Drugs Now screen that were verified to be FGF23 antagonist in Xiao et al. with their IC50 values